The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
11-Jan-21
~$150 million
Target:
Nordic Water
Acquiror:
Sulzer AG
Advising Alder, a Swedish sustainability-focused private equity firm, on the divestment of Nordic Water, a supplier of products for the global water and wastewater treatment market, to Sulzer AG
29-Dec-20
$110 million
Target:
Biogix, Inc.
Acquiror:
Alliance Pharma plc
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
01-Oct-20
$2.6 billion
Target:
Rolls-Royce £2bn Fully Underwritten Rights Issue
Acquiror:
N/A
Advising Rolls-Royce on its Fully Underwritten £2bn Rights Issue, as part of a broader recapitalisation package
22-Sep-20
$465 million
Target:
Windy City Wire Cable & Technology Products
Acquiror:
Diploma PLC
Introduced Diploma PLC, an international group supplying specialized technical products and services, to Windy City Wire Cable & Technology Products, a leading value-add manufacturer and distributor of premium quality, low voltage wire and cable in the US
10-Sep-20
$195 million
Target:
Saga plc
Acquiror:
Sir Roger De Haan
Advised Sir Roger De Haan on his cornerstone investment of £100mm in Saga, the UK provider of products and services exclusively for the over 50s, as part of its £150m equity raise
01-Jul-20
$225 million
Target:
Cello Health plc
Acquiror:
Arsenal Capital Partners
Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States
10-Jun-20
$3.9 billion
Target:
Global collaboration agreement with Genmab A/S
Acquiror:
AbbVie, Inc
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
10-Jun-20
$134 million
Target:
Equity stake in Bupa Arabia
Acquiror:
Bupa Ltd.
Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia
02-Mar-20
$NA
Target:
Global rights (excluding North America) to ThermaCare (United Kingdom)
Acquiror:
Angelini Pharma
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma
20-Feb-20
$NA
Target:
Asia and US rights to Physiogel
Acquiror:
LG Household & Health Care
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd
16-Jan-20
$NA
Target:
Daimler's Mercedes-Benz passenger car and private vans distribution operations in Colombia
Acquiror:
Inchcape PLC
Advised Inchcape, a leading global independent multi-brand automotive distributor, on its acquisition of the Mercedes-Benz passenger car and private vans distribution operations in Colombia from Daimler Colombia
23-Aug-19
$NA
Target:
TT International
Acquiror:
Sumitomo Mitsui Financial Group, Inc.
Advised TT International, a leading independent asset management firm focused on managing high alpha, high conviction active management strategies for institutional investors, on its sale to Sumitomo Mitsui Financial Group, Inc.
17-Jun-19
$80 million
Target:
Renewi Canada
Acquiror:
Convent Capital
Advised Renewi plc, a leading waste to product company, on the sale of its Canadian operations to Convent Capital, an Amsterdam-based investment firm
21-Jan-19
$100 million
Target:
UQM Technologies, Inc.
Acquiror:
Danfoss A/S
Advised Danfoss, a global leader in power solutions, heating, cooling and drives, on its acquisition of UQM Technologies
19-Dec-18
$NA
Target:
Pfizer Inc. Consumer Health Business
Acquiror:
GlaxoSmithKline plc
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture
03-Dec-18
$4.0 billion
Target:
Assets owned by GlaxoSmithKline plc
Acquiror:
Unilever plc / Hindustan Unilever Limited
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
10-Jul-18
$1.1 billion
Target:
The AA plc
Advised the AA plc, the UK’s largest roadside assistance provider, on the refinancing of £825mm of its senior secured facilities
13-May-18
$81 million
Target:
GWA Group Limited’s Door and Access Controls Business
Acquiror:
Allegion plc
Advised Allegion plc, a leading global security products and solutions provider, on the acquisition of GWA Group Limited’s Door & Access Systems Business, a leading provider of door furniture and commercial locksmith services in Australia
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
27-Mar-18
$13.0 billion
Target:
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Acquiror:
GlaxoSmithKline plc
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
26-Feb-18
$224 million
Target:
Crem International
Acquiror:
Welbilt
Advised Welbilt, a leading global provider of commercial foodservice equipment on its acquisition of Crem International, a leading manufacturer of professional coffee machines
22-Jan-18
$375 million
Target:
Lonmin
Advising Lonmin PLC, a major fully integrated producer of Platinum Group Metals, on the amendment of its debt facilities to support the review and implementation of its strategic options
14-Dec-17
$NA
Target:
36.5% stake in DNV GL Group AS
Acquiror:
Det Norske Veritas Holding AS
Advised Det Norske Veritas Holding AS (“DNV”) on its acquisition of the 36.5% stake in DNV GL Group AS it did not already own from Mayfair Vermögensverwaltungs SE, whereby DNV is becoming the sole shareholder and regaining full control of DNV GL
08-Dec-17
$NA
Target:
London & Country Mortgages Limited (“L&C”)
Acquiror:
Experian plc
Advised Experian plc, the world’s leading global information services company, in connection with the acquisition of a 25% stake in L&C, the UK’s largest fee free mortgage adviser